MbrlCatalogueTitleDetail

Do you wish to reserve the book?
Inhibition of redox/Fyn/c‐Cbl pathway function by Cdc42 controls tumour initiation capacity and tamoxifen sensitivity in basal‐like breast cancer cells
Inhibition of redox/Fyn/c‐Cbl pathway function by Cdc42 controls tumour initiation capacity and tamoxifen sensitivity in basal‐like breast cancer cells
Hey, we have placed the reservation for you!
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
You are currently in the queue to collect this book. You will be notified once it is your turn to collect the book.
Oops! Something went wrong.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Inhibition of redox/Fyn/c‐Cbl pathway function by Cdc42 controls tumour initiation capacity and tamoxifen sensitivity in basal‐like breast cancer cells
Oops! Something went wrong.
Oops! Something went wrong.
While trying to remove the title from your shelf something went wrong :( Kindly try again later!
Title added to your shelf!
Title added to your shelf!
View what I already have on My Shelf.
Oops! Something went wrong.
Oops! Something went wrong.
While trying to add the title to your shelf something went wrong :( Kindly try again later!
Do you wish to request the book?
Inhibition of redox/Fyn/c‐Cbl pathway function by Cdc42 controls tumour initiation capacity and tamoxifen sensitivity in basal‐like breast cancer cells
Inhibition of redox/Fyn/c‐Cbl pathway function by Cdc42 controls tumour initiation capacity and tamoxifen sensitivity in basal‐like breast cancer cells

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
How would you like to get it?
We have requested the book for you! Sorry the robot delivery is not available at the moment
We have requested the book for you!
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Inhibition of redox/Fyn/c‐Cbl pathway function by Cdc42 controls tumour initiation capacity and tamoxifen sensitivity in basal‐like breast cancer cells
Inhibition of redox/Fyn/c‐Cbl pathway function by Cdc42 controls tumour initiation capacity and tamoxifen sensitivity in basal‐like breast cancer cells
Journal Article

Inhibition of redox/Fyn/c‐Cbl pathway function by Cdc42 controls tumour initiation capacity and tamoxifen sensitivity in basal‐like breast cancer cells

2013
Request Book From Autostore and Choose the Collection Method
Overview
We found that basal‐like breast cancer (BLBC) cells use Cdc42 to inhibit function of the redox/Fyn/c‐Cbl (RFC) pathway, which normally functions to convert small increases in oxidative status into enhanced degradation of c‐Cbl target proteins. Restoration of RFC pathway function by genetic or pharmacological Cdc42 inhibition enabled harnessing of pro‐oxidant effects of low µM tamoxifen (TMX) concentrations – concentrations utilized in trials on multiple tumour types – to suppress division and induce death of BLBC cells in vitro and to confer TMX sensitivity in vivo through oestrogen receptor‐α‐independent mechanisms. Cdc42 knockdown also inhibited generation of mammospheres in vitro and tumours in vivo , demonstrating the additional importance of this pathway in tumour initiating cell (TIC) function. These findings provide a new regulatory pathway that is subverted in cancer cells, a novel means of attacking TIC and non‐TIC aspects of BLBCs, a lead molecule (ML141) that confers sensitivity to low µM TMX in vitro and in vivo and also appear to be novel in enhancing sensitivity to a non‐canonical mode of action of an established therapeutic agent. Graphical Abstract Restoration of the redox/Fyn/c‐Cbl pathway via suppression of Cdc42 function in basal‐like breast cancer (BLBC) cells and tumours confers tamoxifen sensitivity in vitro and in vivo .